>latest-news

Mira Pharmaceuticals' MIRA-55 Demonstrates Superior Efficacy Over THC In Preclinical Studies

MIRA Pharmaceuticals unveils potent anxiety treatment, MIRA-55, outperforming THC in preclinical studies.

Breaking News

  • Jul 16, 2024

  • Mrudula Kulkarni

Mira Pharmaceuticals' MIRA-55 Demonstrates Superior Efficacy Over THC In Preclinical Studies

MIRA Pharmaceuticals, Inc., a company in the early stages of pharmaceutical development, has revealed encouraging results from its recent preclinical studies on MIRA-55, an innovative oral pharmaceutical marijuana analog. MIRA-55 is being explored as a potential treatment for anxiety and cognitive decline. The latest findings validate MIRA's previous expectations about MIRA-55's pharmacological characteristics and its potential effectiveness. Notably, these preclinical results compared MIRA-55 directly with THC, marijuana's primary psychoactive ingredient, and yielded promising outcomes.

Initially, MIRA centered its marijuana analog preclinical research program on an oral compound named "MIRA1a." In late 2023, following conversations with contract manufacturers, MIRA began to suspect that MIRA1a was actually a novel molecule with a unique chemical structure, which they subsequently named "MIRA-55." This revelation prompted MIRA to file a global provisional patent application for MIRA-55 in March 2024. At that time, MIRA expressed its belief that MIRA-55 exhibited greater potency and potential efficacy compared to MIRA1a, although further testing was needed to substantiate these preliminary findings. The new test results released today confirm MIRA's initial assessments.

The latest preclinical research, carried out both in vitro and using a mouse model, validates that MIRA-55 presents significant advantages over THC. MIRA-55 exhibited greater efficacy at the CB1 and CB2 cannabinoid receptors compared to THC, with a more pronounced and sustained increase in agonist activity as concentration levels rose. This suggests that MIRA-55 could be more effective in activating key cannabinoid receptors responsible for its therapeutic effects. These findings support MIRA's belief that MIRA-55 could offer stronger and more reliable relief for conditions like anxiety and cognitive decline.

Moreover, MIRA-55 seems to maintain a unique balance between its activity on the CB1 and CB2 receptors, potentially supporting its effectiveness across a wider range of doses. Unlike THC, which tends to lose efficacy at higher doses, MIRA-55 demonstrated robust efficacy even as doses increased. This sustained activity implies that MIRA-55 could provide more consistent and prolonged therapeutic benefits, making it a more promising candidate for its intended uses.

In studies examining its potential to alleviate anxiety, MIRA-55 consistently showed dose-dependent reductions in anxiety-like behaviors. In the Open Field Test and Elevated Plus Maze Test, MIRA-55 demonstrated a more predictable and stronger anxiolytic effect than THC. Testing subjects spent more time in the center of the field and the open arms of the maze, indicating reduced anxiety levels. While THC was effective, its results were more variable and less consistent compared to MIRA-55.

Ad
Advertisement